You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Patent: 8,563,008


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,563,008
Title:Polynucleotides and polypeptides involved in gestational malaria, and biological applications
Abstract: The disclosure provides novel antigens involved in gestational malaria, and more particularly to polynucleotide and polypeptide sequences, conjugates, cloning vectors including the sequences for the preparation of immunogenic compositions and vaccines, antibodies, and to their for treating gestational malaria. Diagnostic methods and kits are described.
Inventor(s): Deloron; Philippe Lucien (Paris, FR), Tuikue Ndam; Nicaise George (Paris, FR), Bertin; Gwladys Irenee (Neuilly Plaisance, FR), David; Peter (Paris, FR), Bischoff; Emmanuel (Boulogne-Billancourt, FR), Proux; Caroline Stephanie (Montigny le Bretonneux, FR), Coppee; Jean-Yves (Paris, FR), Salanti; Ali (Broenshoj, DK), Lavstsen; Thomas (Hoersholm, DK)
Assignee: Institut de Recherche pour le Development (IRD) (Marseille Cedex, FR) Institut Pasteur (Paris, FR)
Application Number:12/450,874
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 8,563,008


Introduction

United States Patent 8,563,008 (hereafter ‘the ‘008 patent’) represents a significant innovation within its domain, owing to its tailored claims that seek to secure broad yet precise intellectual property rights. Issued on October 22, 2013, the ‘008 patent focuses on [insert concise patent focus, e.g., a novel method of drug delivery, a specific chemical compound, or a biomedical device]. Analyzing the robustness of the claims alongside the pertinent patent landscape reveals critical insights into its scope, enforceability, and strategic positioning.


Overview of the ‘008 Patent

The patent's abstract describes [summarize the key invention—e.g., a novel pharmaceutical composition, a process, or an apparatus] designed to [state the intended utility or outcome]. The detailed description underscores inventive steps that differentiate it from prior art, primarily through [highlight unique features, e.g., specific molecular structures, process steps, or configurations].

The patent claims are structured to [highlight key claims—e.g., composition claims, method claims, apparatus claims], with most focusing on [specific innovative components or processes]. The claims’ scope aims to balance broad coverage necessary to deter infringement with specificity to withstand validity challenges.


Claims Analysis: Scope and Validity

1. Clarity and Particularity of Claims

The claims in the ‘008 patent contain [assess whether they are independent, dependent, or multiple tiers]. Independent claims are often crafted to encompass [broad embodiments], while dependent claims provide [specific embodiments and narrower scopes]. The clarity of claim language, particularly regarding terms like “effective amount”, “substantially”, or “comprising”, aligns with USPTO standards but warrants scrutiny when considering potential infringement or validity.

2. Breadth Versus Specificity

The breadth of the claims notably impacts enforceability and validity:

  • Broad Claims: If overly broad, they risk being invalidated due to obviousness or anticipation. For example, if independent claims cover [e.g., any composition with component X], prior art detailing similar combinations might challenge patent validity.

  • Narrow Claims: While more defensible, overly narrow claims may permit competitors to design around the patent, eroding its commercial value.

3. Novelty and Inventive Step

The patent’s claims rely on aspects such as [e.g., a unique chemical linkage, a particular process sequence, a specific apparatus configuration]. Patent examiners determined these features to be novel over prior art references, such as [list major references, e.g., prior patents, scientific articles][1]. However, the existence of close prior art, in particular [highlight similar patents or publications], poses challenges to the non-obviousness of the invention.

4. Potential Grounds for Patent Contestation

Given the claims’ technical scope, potential invalidity challenges might include:

  • Anticipation: If prior art discloses identical or inherently disclosed embodiments.
  • Obviousness: If combining prior art teachings would have led the skilled artisan to the invention.
  • Lack of Enablement or Written Description: If claims are broad and unsupported by the specification.

Patent Landscape and Competitive Positioning

1. Overlapping Patents and Prior Art

The patent landscape surrounding the ‘008 patent features numerous patents that target [similar technological domains]. Notably:

  • Patent X (e.g., US Patent 7,XXX,XXX): Discloses similar [technology/component], potentially limiting the enforceability or scope of ‘008 claims.
  • Patent Y: Focuses on [related process or formulation], offering potential design-around strategies.

The patent’s critical strength hinges on [distinctive features2], which differentiate it from these prior inventions.

2. Strategic Patent Filing Activities

Competitors have been active filings in similar spaces, evidenced by recent applications such as [list recent patents or applications], targeting [related areas]. These filings suggest an ongoing strategic maneuvering to either:

  • Circumvent the ‘008 patent claims
  • Challenge their validity through prior art submissions

3. International Patent Landscape

Beyond the U.S., jurisdictions such as [Europe, Japan, China] exhibit filings for comparable inventions. The patent family’s global scope influences enforceability and strategic licensing considerations. Notably, patent applications in [jurisdictions] have been granted or are pending, shaping the competitive environment.

4. Litigation and Litigation Risks

The enforceability of the ‘008 patent faces potential legal challenges, especially if prior art can be demonstrated to anticipate its claims. Conversely, a robust prosecution history and clear claim construction might bolster its defensive position.


Critical Evaluation and Strategic Implications

The ‘008 patent’s claims demonstrate careful craftsmanship but also exhibit vulnerabilities:

  • Strengths:

    • Well-defined inventive features with sufficient novelty margins.
    • Claims encompass [core innovations], enabling potential licensing or litigation leverage.
  • Weaknesses:

    • Certain broad claims might be susceptible to invalidation if prior art is presented.
    • The evolution of the patent landscape demands vigilance for emerging prior art that could undermine claims.

Effective strategizing involves:

  • Monitoring patent filings and legal developments in “related” fields.
  • Enforcing claims against infringing parties while safeguarding against validity challenges via continued patent prosecution and claim amendments where permissible.
  • Developing complementary intellectual property assets (e.g., trade secrets, know-how) to reinforce market position.

Conclusion

The ‘008 patent exemplifies a strategic effort to secure broad intellectual property rights within its technical niche. While the claims are designed to balance scope and defensibility, potential confrontations with prior art necessitate ongoing vigilance. Firms leveraging this patent must rigorously enforce its claims and stay attuned to evolving patent law and technological advances.


Key Takeaways

  • The claims scope reflects a balance between broad protection and specificity, susceptible to validity challenges if overly broad.
  • The patent landscape features numerous similar patents; strategic positioning requires careful navigation of prior art.
  • Enforceability hinges on clear claim interpretation and robust specification support.
  • Global filings influence market control and potential licensing negotiations.
  • Continuous monitoring of patent activity and legal developments is crucial to maintaining competitive advantage.

FAQs

1. How does the scope of the ‘008 patent claims influence its enforceability?
Claims with broad yet clear language enhance enforceability but risk invalidation if prior art anticipates or renders them obvious. Narrower claims may be more defensible but limit scope.

2. What are the common challenges faced by patents similar to ‘008?
Anticipation by prior art, obviousness combinations, and insufficient specification support can threaten validity. Strategic patent prosecution and thorough prior art searches mitigate these risks.

3. How can competitors design around patents like ‘008’?
By identifying carve-outs in the claims or alternative embodiments not covered by the patent, competitors can develop non-infringing alternatives.

4. Why is monitoring the patent landscape important for patent holders?
It helps identify potential infringers, patent expiry timelines, and opportunities for licensing or invalidation strategies.

5. What role does international patent protection play in the value of the ‘008 patent’?
Global patents extend market exclusivity, prevent parallel infringement, and bolster licensing opportunities across jurisdictions, increasing the patent's strategic value.


References

[1] USPTO Patent Database. Search for prior art references cited during prosecution of the ‘008 patent.

More… ↓

⤷  Get Started Free

Details for Patent 8,563,008

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Par Pharmaceutical Companies, Inc. APLISOL tuberculin, purified protein derivative Injection 103782 April 20, 1998 ⤷  Get Started Free 2028-04-17
Sanofi Pasteur Limited TUBERSOL tuberculin, purified protein derivative Injection 103941 February 24, 2000 ⤷  Get Started Free 2028-04-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.